Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q3 2024 · 10-Q
Revenue$336.25M$336.25M+10.1% vs Q3 2023 Net Income$31.24M$31.24M−5.2% vs Q3 2023 EPS Diluted$0.61$0.61−4.7% vs Q3 2023 Gross Profit$177,867,000+12.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived-$540,000N/M Free Cash Flowderived-$15,186,000N/M Margins · derivedGross margin52.9%+0.9 pt vs Q3 2023
Operating margin13.7%−0.5 pt vs Q3 2023
Net margin9.3%−1.5 pt vs Q3 2023
ended Dec 30, 2023 · filed Feb 8, 2024 · 40 d after period end